News
Media Advisory
Huge response to upcoming CADTH webinar on remdesivir and hydroxychloroquine shows demand among health care decision-makers for evidence on the effectiveness of these therapies.
Ottawa, Ontario — More than 1,500 people have registered for a CADTH webinar that will provide an overview of the available science behind remdesivir an...
CADTH has received the following notice(s) of pending drug submission(s).
Brand name
Zolgensma
Generic name
onasemnogene abeparvovec
Manufacturer
Novartis Pharmaceuticals Canada Inc.
Indication(s)
Spinal muscular atrophy (SMA), pediatrics
Project Number
SG0649-000
Call for pat...
A new project on Flash Glucose Monitoring System FreeStyle Libre to Monitor Glycemia in Patients With Diabetes is now available for feedback from all interested stakeholders.
Flash Glucose Monitoring System FreeStyle Libre to Monitor Glycemia in Patients With Diabetes
Call for Feedback: 2020-05-22
Feedback Due By: 2020-06-04
Consultation Docum...
A new project on Stereotactic Ablative Body Radiotherapy for the Treatment of Oligometastatic Cancer is now available for feedback from all interested stakeholders.
Stereotactic Ablative Body Radiotherapy for the Treatment of Oligometastatic Cancer
Call for Feedback: 2020-05-22
Feedback Due By: 2020-06-04
Consultation Document: List of Include...
OTTAWA – The CADTH Board of Directors announced today that Suzanne McGurn has been appointed as the next President and Chief Executive Officer of CADTH, effective July 6, 2020.
Ms. McGurn will succeed Dr. Brian O’Rourke, who announced his retirement from CADTH in October 2019 after serving as President and Chief Executive Officer since 2010. D...
